vs
Cellectis S.A.（CLLS）与Revolution Medicines, Inc.（RVMD）财务数据对比。点击上方公司名可切换其他公司
Cellectis S.A.自由现金流更多（$27.6M vs $-139.5M）
Cellectis S.A.是一家法国生物制药公司，专注于开发用于癌症免疫治疗的基因编辑嵌合抗原受体T细胞技术，目前在巴黎、纽约以及北卡罗来纳州罗利均设有办公机构，在肿瘤免疫基因编辑疗法领域拥有多年研发积累。
Tempus AI是美国健康科技企业，2015年由埃里克·莱夫科夫斯基在伊利诺伊州芝加哥创立，成立契机为其妻子确诊乳腺癌。公司依托数据与人工智能技术，为肿瘤、心脏病、放射医学、抑郁症等领域提供包含诊断在内的精准医疗服务，2024年6月14日于纳斯达克上市，股票代码为TEM。
CLLS vs RVMD — 直观对比
营收规模更大
CLLS
是对方的Infinity倍
$0
自由现金流更多
CLLS
多$167.1M
$-139.5M
损益表 — Q2 2024 vs Q4 2024
| 指标 | | |
|---|---|---|
| 营收 | $9.5M | $0 |
| 净利润 | $-25.3M | $-194.6M |
| 毛利率 | — | — |
| 营业利润率 | -181.1% | — |
| 净利率 | -265.9% | — |
| 营收同比 | 375.0% | — |
| 净利润同比 | -51.9% | -20.4% |
| 每股收益（稀释后） | $-0.28 | $-1.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLLSRVMD
| Q4 24 | — | $0 | ||
| Q3 24 | — | $0 | ||
| Q2 24 | $9.5M | $0 | ||
| Q1 24 | — | $0 | ||
| Q4 23 | — | $742.0K | ||
| Q3 23 | $1.6M | $0 | ||
| Q2 23 | $2.0M | $3.8M | ||
| Q1 23 | — | $7.0M |
净利润CLLSRVMD
| Q4 24 | — | $-194.6M | ||
| Q3 24 | — | $-156.3M | ||
| Q2 24 | $-25.3M | $-133.2M | ||
| Q1 24 | — | $-116.0M | ||
| Q4 23 | — | $-161.5M | ||
| Q3 23 | $-17.5M | $-108.4M | ||
| Q2 23 | $-16.6M | $-98.3M | ||
| Q1 23 | — | $-68.1M |
毛利率CLLSRVMD
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | 97.3% | — | ||
| Q1 23 | — | — |
营业利润率CLLSRVMD
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -181.1% | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | -24256.5% | ||
| Q3 23 | -1258.1% | — | ||
| Q2 23 | -1180.5% | -2845.1% | ||
| Q1 23 | — | -1071.5% |
净利率CLLSRVMD
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -265.9% | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | -21770.5% | ||
| Q3 23 | -1064.1% | — | ||
| Q2 23 | -831.6% | -2570.6% | ||
| Q1 23 | — | -970.9% |
每股收益（稀释后）CLLSRVMD
| Q4 24 | — | $-1.13 | ||
| Q3 24 | — | $-0.94 | ||
| Q2 24 | $-0.28 | $-0.81 | ||
| Q1 24 | — | $-0.70 | ||
| Q4 23 | — | $-1.23 | ||
| Q3 23 | $-0.31 | $-0.99 | ||
| Q2 23 | $-0.20 | $-0.92 | ||
| Q1 23 | — | $-0.72 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $149.0M | $2.3B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $148.6M | $2.3B |
| 总资产 | $407.1M | $2.6B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CLLSRVMD
| Q4 24 | — | $2.3B | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | $149.0M | $1.6B | ||
| Q1 24 | — | $1.7B | ||
| Q4 23 | — | $1.9B | ||
| Q3 23 | — | $813.2M | ||
| Q2 23 | $84.4M | $909.5M | ||
| Q1 23 | — | $909.8M |
股东权益CLLSRVMD
| Q4 24 | — | $2.3B | ||
| Q3 24 | — | $1.6B | ||
| Q2 24 | $148.6M | $1.6B | ||
| Q1 24 | — | $1.7B | ||
| Q4 23 | — | $1.8B | ||
| Q3 23 | $76.1M | $837.5M | ||
| Q2 23 | $96.6M | $930.8M | ||
| Q1 23 | — | $952.2M |
总资产CLLSRVMD
| Q4 24 | — | $2.6B | ||
| Q3 24 | — | $1.8B | ||
| Q2 24 | $407.1M | $1.8B | ||
| Q1 24 | — | $1.9B | ||
| Q4 23 | — | $2.1B | ||
| Q3 23 | $209.7M | $984.2M | ||
| Q2 23 | $227.7M | $1.1B | ||
| Q1 23 | — | $1.1B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $28.9M | $-138.3M |
| 自由现金流经营现金流 - 资本支出 | $27.6M | $-139.5M |
| 自由现金流率自由现金流/营收 | 290.5% | — |
| 资本支出强度资本支出/营收 | 13.2% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-567.7M |
8季度趋势，按日历期对齐
经营现金流CLLSRVMD
| Q4 24 | — | $-138.3M | ||
| Q3 24 | — | $-130.4M | ||
| Q2 24 | $28.9M | $-128.2M | ||
| Q1 24 | — | $-160.6M | ||
| Q4 23 | — | $-120.6M | ||
| Q3 23 | — | $-100.5M | ||
| Q2 23 | $-47.4M | $-67.1M | ||
| Q1 23 | — | $-62.4M |
自由现金流CLLSRVMD
| Q4 24 | — | $-139.5M | ||
| Q3 24 | — | $-133.9M | ||
| Q2 24 | $27.6M | $-130.6M | ||
| Q1 24 | — | $-163.7M | ||
| Q4 23 | — | $-122.9M | ||
| Q3 23 | — | $-103.0M | ||
| Q2 23 | $-47.9M | $-68.2M | ||
| Q1 23 | — | $-64.1M |
自由现金流率CLLSRVMD
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 290.5% | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | -16560.6% | ||
| Q3 23 | — | — | ||
| Q2 23 | -2391.4% | -1784.5% | ||
| Q1 23 | — | -914.6% |
资本支出强度CLLSRVMD
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 13.2% | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | 312.3% | ||
| Q3 23 | — | — | ||
| Q2 23 | 24.1% | 29.3% | ||
| Q1 23 | — | 25.1% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
